Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search methodology
PubMed 21263450 · doi:10.1038/nrendo.2010.217
What was done
This narrative review synthesizes the etiology, pathogenesis, diagnostic framework, evolutionary theories, and clinical management strategies for polycystic ovary syndrome (PCOS).
What was found
The abstract reports that PCOS has a prevalence of up to 10% in women of reproductive age. Core diagnostic criteria focus on hyperandrogenism and/or hyperandrogenemia, oligo-ovulation, and polycystic ovarian morphology after excluding other causes. Insulin resistance is noted in a majority of cases, where hyperinsulinemia stimulates ovarian androgen secretion and inhibits hepatic sex hormone-binding globulin production. Associated conditions listed include infertility, obstetrical complications, type 2 diabetes, cardiovascular disease, and mood and eating disorders; no other numerical data are provided in the abstract.
Why it matters
It summarizes the clinical framework linking metabolic dysfunction, insulin resistance, and androgen excess to guide diagnosis and treatment strategies targeting both reproductive and cardiometabolic complications.
Limits
This is a narrative review with no systematic search methodology, risk of bias assessment, or quantitative pooling. No original patient data or detailed statistical effect sizes are reported in the abstract.
Cited by
- supports High insulin levels in PCOS inhibit hepatic production of sex hormone-binding globulin (SHBG), thereby increasing circulating free androgen and testosterone concentrations.